100 related articles for article (PubMed ID: 1692295)
1. Sandostatin and carcinoid tumours in France: experience in the Lyon area.
Chayvialle JA
Digestion; 1990; 45 Suppl 1():23-6. PubMed ID: 1692295
[TBL] [Abstract][Full Text] [Related]
2. Sandostatin desensitization--a strategy useful for patients with carcinoid tumors, intolerant to sandostatin.
Vinjamaram S; Iyer R
Cancer Chemother Pharmacol; 2011 Jul; 68(1):225-6. PubMed ID: 20922390
[TBL] [Abstract][Full Text] [Related]
3. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
Janson ET; Oberg K
Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
[TBL] [Abstract][Full Text] [Related]
4. Sandostatin and the Hammersmith experience.
Wynick D; Bloom SR
Digestion; 1990; 45 Suppl 1():5-9; discussion 9-10. PubMed ID: 2335269
[TBL] [Abstract][Full Text] [Related]
5. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
Garland J; Buscombe JR; Bouvier C; Bouloux P; Chapman MH; Chow AC; Reynolds N; Caplin ME
Aliment Pharmacol Ther; 2003 Feb; 17(3):437-44. PubMed ID: 12562458
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Oberg K; Norheim I; Theodorsson E
Acta Oncol; 1991; 30(4):503-7. PubMed ID: 1854508
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
Arnold R; Trautmann ME; Creutzfeldt W; Benning R; Benning M; Neuhaus C; Jürgensen R; Stein K; Schäfer H; Bruns C; Dennler HJ
Gut; 1996 Mar; 38(3):430-8. PubMed ID: 8675099
[TBL] [Abstract][Full Text] [Related]
9. Sandostatin (octreotide acetate) injection/Sandoz.
Swartz ML
Gastroenterol Nurs; 1990; 13(2):95-7. PubMed ID: 1963085
[TBL] [Abstract][Full Text] [Related]
10. Effects of sandostatin on neuroendocrine tumours of the gastrointestinal system.
Buchanan KD
Recent Results Cancer Res; 1993; 129():45-55. PubMed ID: 8394596
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
[TBL] [Abstract][Full Text] [Related]
12. Abdominal carcinoid tumours in Sheffield.
Woods HF; Bax ND; Ainsworth I
Digestion; 1990; 45 Suppl 1():17-22. PubMed ID: 2335266
[TBL] [Abstract][Full Text] [Related]
13. Sandostatin and the Belfast experience.
Buchanan KD; Collins JS; Varghese A; Johnston CF; Shaw C
Digestion; 1990; 45 Suppl 1():11-4; discussion 15-6. PubMed ID: 2159429
[TBL] [Abstract][Full Text] [Related]
14. Carcinoid tumours and the role of Sandostatin.
Woods HF
NATNEWS; 1989 Jul; 26(7):13-5. PubMed ID: 2779638
[No Abstract] [Full Text] [Related]
15. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
16. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
[TBL] [Abstract][Full Text] [Related]
17. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
18. [Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
Lipp RW; Hammer HF; Passath A; Dobnig H; Ramschak-Schwarzer S; Stiegler C; Leb G; Krejs GJ
Acta Med Austriaca; 1993; 20(1-2):42-4. PubMed ID: 8475679
[TBL] [Abstract][Full Text] [Related]
19. Management of disseminated midgut carcinoid tumours.
Ahlman H; Wängberg B; Jansson S; Stenqvist O; Geterud K; Tylén U; Caidahl K; Scherstén T; Tisell LE
Digestion; 1991; 49(2):78-96. PubMed ID: 1724766
[TBL] [Abstract][Full Text] [Related]
20. Octreotide treatment of carcinoid syndrome: analysis of published dose-titration data.
Harris AG; Redfern JS
Aliment Pharmacol Ther; 1995 Aug; 9(4):387-94. PubMed ID: 8527614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
